** Shares of vaccine maker Moderna MRNA.O rise 9.2% to $33.19 premarket
** CEO Stephane Bancel has bought ~160,000 MRNA shares at roughly $31/shr, SEC filing showed late Tuesday
** MRNA shares have fallen 39.1% since mid-January, when co cut 2025 sales forecast by $1 bln
** Co has ~385 million outstanding shares, as of February 14
** Stock fell 68.3% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.